Eli Lilly’s Foundayo 17.2 mg shows greater weight loss at 52 weeks

Reuters briefs says Foundayo (orforglipron) 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1c reduction versus oral semaglutide 25 mg at 52 weeks in an indirect treatment comparison (Achieve-3).